Solana (NASDAQ:HSDT – Get Free Report) and StoneCo (NASDAQ:STNE – Get Free Report) are both finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.
Valuation and Earnings
This table compares Solana and StoneCo”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Solana | $6.02 million | 22.85 | -$40.89 million | ($30.32) | -0.08 |
| StoneCo | $2.53 billion | 0.96 | $425.73 million | $2.48 | 3.92 |
Institutional and Insider Ownership
18.6% of Solana shares are owned by institutional investors. Comparatively, 73.2% of StoneCo shares are owned by institutional investors. 14.4% of Solana shares are owned by company insiders. Comparatively, 11.3% of StoneCo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Solana and StoneCo’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Solana | -1,302.78% | -41.86% | -18.53% |
| StoneCo | 22.92% | 22.19% | 4.10% |
Analyst Recommendations
This is a breakdown of current recommendations for Solana and StoneCo, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Solana | 1 | 1 | 3 | 0 | 2.40 |
| StoneCo | 0 | 6 | 4 | 0 | 2.40 |
Solana presently has a consensus target price of $3.75, indicating a potential upside of 64.84%. StoneCo has a consensus target price of $14.30, indicating a potential upside of 47.04%. Given Solana’s higher probable upside, research analysts plainly believe Solana is more favorable than StoneCo.
Risk and Volatility
Solana has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, StoneCo has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500.
Summary
StoneCo beats Solana on 10 of the 13 factors compared between the two stocks.
About Solana
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.
About StoneCo
StoneCo Ltd. provides financial technology and software solutions to merchants and integrated partners to conduct electronic commerce across in-store, online, and mobile channels in Brazil. It distributes its solutions, principally through proprietary Stone Hubs, which offer hyper-local sales and services; and sells solutions to brick-and-mortar and digital merchants through sales team. The company served small-and-medium-sized businesses; and marketplaces, e-commerce platforms, and integrated software vendors. StoneCo Ltd. was founded in 2000 and is headquartered in George Town, the Cayman Islands.
Receive News & Ratings for Solana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solana and related companies with MarketBeat.com's FREE daily email newsletter.
